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We wish to report some corrections to our study [1], none of
which alters the interpretation of the data or the conclusions
drawn. After publication, we noticed that one of the micro-
array hybridizations (on sample NB11) was performed on the
same patient’s material as another hybridization (sample
NB4; see Table 1; a corrected version of Table 5 [1]). As this
error leads to an incorrect subclassification of the patients
into the ‘favourable’ and ‘unfavourable’ neuroblastoma
subgroups, we would like to exclude this data point from the
differential expression analysis of favorable versus un-
favorable neuroblastoma given under the heading ‘Differen-
tial expression analysis of favorable and unfavorable
neuroblastoma’ in the Results section of [1]. Careful
reanalysis after exclusion of NB11 did not lead to important
changes in the generated gene lists and conclusions; the
changes are given in the corrected paragraph and Table 2 (a
corrected version of Table 4 [1]), and the Additional data
files 1 and 2 (corrected versions of Additional data files 2 and
3 [1]) available online with this article.
We also noticed that sample NB1 is stage 1 instead of stage
4S and that sample NB2 was not localized to the adrenals
(see Table 1).
Results
Differential expression analysis of favorable and 
unfavorable neuroblastoma
So far, most published microarray studies on neuroblastomas
mainly compared favorable with unfavorable neuroblastomas
in order to identify prognostic markers or pathways that are
involved in these clearly different neuroblastoma tumor
types. In order to add value to such an analysis, we contrasted
similar differentially expressed gene lists with the normal
neuroblast expression profile (Additional data file 1). In a
first step, we compared the differentially expressed genes
between these two tumor types with published prognostic
gene lists. We found that 23 of the 193 genes on our list were
previously reported, including the well established markers
MYCN, NTRK1, and CD44 (see NBGS analysis in Additional
data file 2). This overlap demonstrates the validity of the
selected neuroblastoma panel and their expression profile.
Subsequently, we looked for the corresponding gene expres-
sion levels of the differentially expressed genes in the normal
counterpart cells, aiming to select neuroblastoma candidate
genes. Of the 100 genes that are more highly expressed in
favorable tumors (compared to unfavorable) 41 also have a
significant differential expression (either higher or lower)compared to neuroblasts, whereas 43 of the 93 genes that
are more highly expressed in unfavorable tumors exhibit dif-
ferential expression compared to the neuroblasts (Table 2).
From this analysis, a few putative positional tumor suppressor
candidates emerge: CDC42 on 1p36, CACNA2D3 on 3p21
and  DLK1 on 14q. The latter two genes are of particular
interest because they are highly expressed in neuroblasts
and favorable neuroblastomas and their expression is signif-
icantly lower in unfavorable neuroblastomas. Among the
genes that are more highly expressed in unfavorable neurob-
lastomas than in favorable ones and neuroblasts, the proven
oncogenic transcription factor MYCN emerges (and putative
downstream genes KIFAP3, OPHN1, RGS7, ASCL1, ODC1,
TWIST1 and TYMS, according to NBGS), as well as several
other genes that have been identified or studied in the
context of neuroblastoma such as ALK and  PRAME, and
positional candidates on 17q including BIRC5 and RNU2.
Additional data files
Additional data files 1 and 2 containing the corrected data
available online with this article.
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Table 1
Clinical and genetic data of carefully selected neuroblastoma samples that were included in this study
Sample  Lab  % Tumor  MYCN  Adrenal  Overall survival 
number number cells Stage amp Ploidy localization Age Dead/alive (months) Type
NB1 98T33 95 1 No Tri Yes < 1 year Alive 76.9 Favorable
NB2 99T84 90 1 No Tri No < 1 year Alive 71.8 Favorable
NB3 96T82 90 1 No Tri Yes < 1 year Alive 115.5 Favorable
NB4 99T129 90 1 No Tri Yes < 1 year Alive 71.7 Favorable
NB5 01T28 90 4 Yes Di Yes > 1 year Dead 5.6 Unfavorable
NB6 03T304 100 3* No Di Abdominal > 1 year Alive 12.0 Unfavorable
NB7 03T236 90 4 No ND Yes > 5 year Dead 19.4 Unfavorable
NB8 00T54 70 1 No Tri Yes < 1 year Alive 62.6 Favorable
NB9 00T35 >95 4 Yes Di Yes < 1 year Dead 13.7 Unfavorable
NB10 99T125 80 3 No Di Yes > 5 year Alive 79.3 Unfavorable
NB11 = NB4 99T129 90 1 No Tri Yes < 1 year Alive 71.7 Favorable
NB12 02T192 100 4 Yes Di Abdominal > 5 year Dead 16.2 Unfavorable
NB13 D031 >95 4 No Di Abdominal > 1 year Dead 64.8 Unfavorable
NB14 E002 >80 4 No ND Abdominal > 1 year Alive 65.7 Unfavorable
NB15 E037 >80 4 No ND Abdominal > 1 year Alive 45.3 Unfavorable
NB16 E044 >80 4 No ND Yes < 1 year Alive 37.0 Unfavorable
NB17 E121 >80 4 Yes ND Abdominal > 1 year Dead 78.4 Unfavorable
NB18 04T121 60 3 Yes Di Yes > 1 year Dead 6 Unfavorable
Samples were subdivided into favorable or unfavorable type based on MYCN amplification, ploidy and age at diagnosis. *Neuroblastoma or nodular gan-
glioneuroblastoma. ND, not determined or unknown.
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Table 2
Genes that are differentially expressed in favorable vs unfavorable neuroblastoma
Favorable NB > unfavorable NB NBGS Favorable NB < unfavorable NB NBGS
neuroblast < favorable NB neuroblast < favorable NB, neuroblast < unfavorable NB
AKAP7 6q - FABP6 5q -
ARL4C 2q - IGLJ3 22q 1
ASPN 9q - NEFL 8p -
BCL2 18q 1 NPY 7p -
CALB1 8q -
CAMK2B 22q 2 neuroblast < unfavorable NB
CD24 6q -
CDC42 1p 1 ALK 2p -
DDAH1 1p - ASCL1 12q 1
DNAPTP6 2q - BCL11A 2p -
EPB41L3 18p 1 BIRC5 17q 3
FAM70A Xq - C3 19p -
KIFAP3 1q 1 CALCB 11p -
OPHN1 Xq - CCL18 17q -
PPAN 19p - CCL21 9p -
PRKCB1 16p 1 CCNB1 5q 1
REEP1 2p - CD74 5q -
RGS7 1q 2 CRH 8q -
RNF11 1p - CSPG3 19p -
SCD5 4q 2 CXCR4 2q 2
SERINC1 6q 1 DYNC1I1 7q -
ST6GALNAC5 1p - F12 5q -
SV2C 5q - GFRA2 8p -
IGHA1 14q 2
neuroblast > favorable NB, neuroblast > unfavorable NB IGHG3 14q -
IGHM 14q -
CACNA2D3 3p - IGKC 2p 1
DLK1 14q 2 IGLC1 22q -
HBG1 11p - IGLC2 22q -
HBG2 11p - LMO3 12p 1
MMP9 20q 1
neuroblast > unfavorable NB MYCN 2p 9
NEFH 22q -
ALDH3A2 17p 1 ODC1 2p 3
DBH 9q 1 OGDHL 10q -
DLC1 8p - P2RX5 17p -
EYA1 8q - PRAME 22q 1
GCH1 14q 1 RPS4Y1 Yp 1
HBA1 16p - SERPINF1 17p -
HBA2 16p - SIX3 2p -
NTRK1 1q 4 SST 3q 1
PTPRD 9p - TNFRSF10B 8p 2
PTPRK 6q - TWIST1 7p 1
SFRP1 8p 1 XAGE1 Xp -
SLC18A1 8p -
TFAP2B 6p - neuroblast > favorable NB
TLN2 15q 1
RNU2 17q -
neuroblast > favorable NB, neuroblast > unfavorable NB
C11orf43 11p -
Genes that are differentially expressed compared with neuroblasts among the differentially expressed genes in favorable neuroblastoma (NB) vs 
unfavorable NB, with an indication of the number of neuroblastoma microarray studies in which these genes were found through NBGS analysis. 
NBGS, Neuroblastoma Gene Server.